NeoGenomics (NEO) Reports In-Line Q3 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. ETSY
9. CVNA
10. CHDN

Go back to NeoGenomics (NEO) Reports In-Line Q3 Loss

NeoGenomics Reports Revenue of $25.1 Million and Record Adjusted EBITDA of $2.8 Million Driven by a 25% Increase in Test Volume in the Third Quarter of 2015

October 29, 2015 7:02 AM EDT

FT. MYERS, Fla., Oct. 29, 2015 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter of 2015.

Third Quarter 2015 Highlights:

25% growth in base(1) test volume 8% growth in consolidated revenue despite $1.9 million reduction in FISH reimbursement 12.5% reduction in Avg. Cost per Test in base(1) business Adjusted EBITDA(2) increase to a record high $2.8 million and EPS of ($.00) per share

Consolidated Revenue for the third... More

NeoGenomics Amends Strategic Alliance Agreement with Covance Central Laboratory Services

October 28, 2015 7:08 PM EDT

FT. MYERS, Fla., Oct. 28, 2015 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today an amended Strategic Alliance Agreement with Covance Central Laboratory Services. 

The Strategic Alliance Agreement, originally executed on Nov. 18, 2013, established NeoGenomics and Covance as mutually exclusive partners for the provision of NeoGenomics' specialty laboratory services, including certain anatomic pathology and histology testing, for Covance's central laboratory customers.  The amendment, which reflects the February 2015 merger of Covance and Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), will... More